Vitamin K2 therapy for a patient with myelodysplastic syndrome TO 
THE EDITOR
Myelodysplastic syndrome (MDS) is an acquired stem cell disorder most likely arising from a genetic lesion in a single mulipotent hematopoietic stem cell that often progresses to overt acute myeloid leukemia (post-MDS AML). The syndrome predominantly affects the elderly, with a median age of 60 to 70 years. Intensive chemotherapy achieves an acceptable response rate, but the high incidence of treatment-related death and the short duration of complete remission mean that there is no survival benefit. 1 High-dose chemotherapy supported by allogenic bone marrow transplantation is the only potentially curative treatment for MDS, however, such therapy can only be offered to a few younger patients. 2 Since the prognosis of MDS in the elderly is poor, establishment of a novel strategy for treating these patients has been an urgent issue. We have previously reported that vitamin K2 (VK2) analogs such as menaquinone (MK)-3, -4 and -5, but not vitamin K1, have a potent apoptosis-inducing effect on various types of primary cultured leukemic cells, including post-MDS AML cells. 3 In addition, we recently demonstrated that this apoptosis-inducing effect is rather selective for blast cells, as assessed by flow cytometry of whole marrow mononuclear cells from patients who had refractory anemia with excess of blast (RAEB) or RAEB in transformation. 4 In contrast, VK2 was reported to show some differentiation-inducing activity on acute myeloid leukemic cell lines such as HL-60 and U937 in vitro.
5 MK4 has been used clinically for the treatment of the patients with osteoporosis in Japan. The safety of daily doses of MK4 up to 135 mg orally over 24 weeks has already been confirmed in a late phase II trial for osteoporosis. 6 These findings suggested that VK2 may be useful for the treatment of patients with MDS in blastic transformation.
A 65-year-old man was referred to our department because of thrombocytopenia and anemia. Peripheral blood examination showed leukoerythroblastosis with morphological abnormalities such as hypogranulation and pseudo-Pelger nuclear abnormality of neutrophils, giant platelets, micromegakaryocytes, and binuclear erythroblasts with megaloblastic change. He was diagnosed as having MDS with myelofibrosis by bone marrow trephine. The percentage of blast cells in his peripheral blood soon reached over 30%, indicating progression to the overt acute leukemic phase ( Table 1 ). As we also found previously in other MDS patients, 5 culture of his peripheral mononuclear cells in the presence of 3 and 10 m MK4 for 72 h resulted in selective elimination of CD34 ++ /CD33 dull+ blast cells in a dose-dependent manner ( Figure 1 ). Because his fibrotic marrow made him unable to tolerate intensive chemotherapy, oral administration of 90 mg of MK4 daily was started after obtaining informed consent. Six weeks after initiation of MK4 therapy, the peripheral blast cell count has significantly decreased and the platelet count has increased from 31 × 10 9 /l to 133 × 10 9 /l (Table 1) . Thereafter, the dose of MK4 was reduced to 45 mg/day, and treatment was continued. This has resulted in maintaining a good per- formance status for over 10 months without any myeloablative therapy, although a few percent of blast cells are still detectable in the peripheral blood. No side-effects of MK4, including myelosuppression have been detected. It is still not clear whether his hematological improvement was achieved because of the induction of apoptosis or differentiation of blast cells in response to VK2 therapy. However, our observation strongly suggests the clinical benefit of using non-toxic VK2 for the treatment of MDS, especially in elderly patients. A formal clinical trial also seems to be warranted.
M Yaguchi 1st Department of Internal Medicine
Tokyo, K Toyama Japan 
COMMENTS ON A PUBLISHED PAPER
A more precise diagnosis of AML M0, a part of which exhibits a near-tetraploid karyotype TO . Both patients died of pancytopenia after induction treatments on the 24th and 52nd day of therapy, respectively. Recently we have shown 3 that at least six of 17 patients with near-tetraploid AML were classified as AML M0, often with erythroid and/or megakaryocytic dysplasia pointing to their origin in myeloid pluripotent progenitors. Near-tetraploid karyotype is easily morphologically recognized by the large blast size. 2, 3 Thus, AML M0 in a proportion of cases may be a subtype of near-tetraploid AML and in a further proportion a subtype of AML with a complex karyotype in the morphologic, immunologic, and cytogenetic (MIC) classification.
